

Boston Scientific and Angiotech Win Patent Infringement Case Against Sahajanand in the Netherlands

Natick, MA and Vancouver, BC (May 3, 2006) -- Boston Scientific Corporation (NYSE: BSX) and Angiotech Pharmaceuticals, Inc (NASDAQ: ANPI, TSX: ANP) announced today that they received a favorable decision from a Dutch court in a patent dispute against Sahajanand Medical Technologies Pvt. Ltd. Boston Scientific and Angiotech alleged that Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent directed to paclitaxel stents. The Court found that the asserted claims were infringed and valid.

The Court granted Boston Scientific and Angiotech an injunction against Sahajanand, prohibiting the company from selling, bringing onto the market and delivering -- as well as importing, offering or keeping in stock for one of these purposes -- the infringing Infinnium paclitaxel stent in the Netherlands. The Court also ordered Sahajanand to pay damages and/or surrender profits resulting from the infringement. The Court's decision can be appealed by Sahajanand.

"We are pleased the Dutch court upheld the validity of this important patent and found that it had been infringed," said Paul LaViolette, Chief Operating Officer of Boston Scientific.

"This is a significant victory in a key area of our intellectual property," said Dr. William L. Hunter, President and CEO of Angiotech Pharmaceuticals.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

About Angiotech Pharmaceuticals

Founded in 1992 Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, with 14 facilities in 6 countries and over 1,700 dedicated employees, that discovers, develops and markets innovative, minimally invasive treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.

Boston Scientific -- This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

Angiotech Pharmaceuticals -- Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place

undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

CONTACTS:

Boston Scientific:

Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation

Angiotech:

Analysts and Investors:
Janet Craig, VP, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(604) 221-7676 ext 6933

Media:
Jodi Regts, Manager, Corporate Communications
Angiotech Pharmaceuticals, Inc.
(604) 221-7676 ext 7930